Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours

NCT06921928 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06921928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06921928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 29, 2025
Completion date
December 16, 2027
Enrollment
31 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, gastric cancer, gastroesophageal junction cancer, pancreatic ductal adenocarcinoma